Treatment of normally tumorigenic murine tumor cell lines in vitro with chemical mutagens followed by cloning of the surviving cells, results in the selection, at extraordinarily high frequencies (anywhere from <1% to >90%), of clones unable to grow progressively in normal syngeneic mice (1-7). Such clones, which are phenotypically stable in culture over a period of several weeks or months, have been designated by Boon and his colleagues (1-6) as "tum-" (nontumorigenic in normal hosts). ~ They have been derived using such standard mutagens as N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) and ethyl methanesulfonate (EMS), from at least eight different murine tumors of viral, chemical, or spontaneous origin (1-7). Because the turn-clones will grow readily in highly immunosuppressed recipients, e.g., X-irradiated or nude mice (1-8), the turn-phenotype appears to have an underlying immunological basis, a view confirmed by detailed in vitro studies of T cell-mediated cytotoxicity (CMC).
However, because these frequency rates are many orders of magnitude greater than that predicted by classic genetic (point) mutational events, there is the distinct possibility that an "epigenetic" mechanism is involved. By "epigenetic" we mean a heritable phenotypic change brought about by a mechanism that does not involve a change in the actual sequence of nucleotides in DNA. Such a change can be brought about by "DNA hypomethylation."
Many investigators (reviewed in references 12 and 13) have reported that a drop in the level of 5-methylcytosine in DNA can result in expression of genes that were previously "silent." Such DNA hypomethylation can be achieved by the treatment of cells with the DNA hypomethylating agent 5-azacytidine, an analogue of the DNA base, cytosine. This can result in high frequency phenotypic alterations (in the order of 10%) as a result of alteration in gene expression. Furthermore, the altered methylation patterns and levels can be somatically inherited (12, 13) , though not with perfect fidelity (14) , thereby raising the distinct possibility that "methylation changes can masquerade as mutations" (13) . Finally, a number of investigators have reported that many mutagens (including EMS and MNNG) and carcinogens can themselves cause hypomethylation of DNA (13, (15) (16) (17) . It therefore seemed reasonable to hypothesize that hypomethylation of DNA could explain the high frequency at which the turn-clones are generated after mutagen treatment. We therefore decided to test the tumorigenic and immunologic properties of tumor cell clones that had been pretreated with EMS or 5-azacytidine. The results demonstrate that 5-azacytidine can cause virtually the same changes as EMS, despite an absence of any significant mutagenic effect in the treated cells.
Materials and Methods
Animals. DBA/2 and A/J strain mice 5-6 wk old, were purchased from The Jackson Laboratory, Bar Harbor, ME. BALB/c-nu/nu mouse breeding pairs were originally obtained from the National Institutes of Health (NIH) and are currently maintained in a nude mouse colony established in the research facilities of the Long Beach Veterans Administration Hospital. In all experiments aimed at assessing the growth potential of turn-variants, both nu/nu and nu/+ heterozygous littermates were challenged with tumor.
Tumors. The origin and characteristics of the MDAY-D2 tumor have been described in detail elsewhere (18, 19) . The P815 mastocytoma was obtained from Dr. R. Herberman (NIH). The TA3 mammary adenocarcinoma was obtained through Dr. Joseph G. Mayo, NIH, and Dr. Arthur Bodgen, Mason Research Institute Tumor Bank, Worcester, MA. Tumor cells were maintained in culture or by weekly intraperitoneai passage. All cell lines were routinely tested to assure that they were free of Mycoplasma by Dr. Eric Stanbridge (Department of Microbiology, UCLA/Irvine). Only Mycoplasma-free cell lines were used in these studies.
Treatment of Cells with Mutagens. Treatment of tumor cells with MNNG was performed according to the methods of Boon et al. (1) (2) (3) (4) (5) (6) . Cells (3 x 106 in 5 ml) were exposed to MNNG at 3 #g/ml for 60 min. The cells were washed and placed in culture. Treatment with EMS was according to the method of Gillin et al. (20) . 5 ml of tumor cells at 6 X 105 cells/ml were placed in small, sterile petri dishes and allowed to equilibrate to a 5% CO2 atmosphere in RPMI without fetal calf serum. After 1 h, 2.5 ILl (360 pg/ml) of EMS was added, and the cells were allowed to incubate for 2 h, after which they were centrifuged and incubated in RPMI medium with 10% fetal calf serum. Under these conditions, cell viability is reduced to ~30% after 24 h. This is consistent with the findings of others (1) (2) (3) (4) (5) (6) .
Treatment of Cells with 5-Azacytidine. Treatment with 5-azacytidine was performed
according to the method of P. Jones (personal communication). 5-Azacytidine (final concentration: 3 #M) was added to 5 ml of cells at 6 × 105 cells/ml. The cells were washed after 24 h incubation and allowed to re-grow for 1 wk before cloning. Cell viabilities after 5-azacytidine treatment generally exceeded 90%. After cloning, cells from individual clones were injected subcutaneously (5 × 105 cells) into syngeneic mouse hosts. Clones that failed to grow were tested again, i.e., they were reinjected into normal syngeneic hosts twice more to assess the stability of the tum-phenotype. In addition, individual tum-clones were injected into nude mice and each was also assessed for its ability to protect against a parent tumor challenge and to induce a cytotoxic T lymphocyte (CTL) response.
Assessment ofT Cell Cytotoxicity. A standard method to induce secondary CTL responses was used which involves in vitro restimulation (7, 18) . Three DBA/2 or A/J strain mice were given subcutaneous injections of 5 × 10 ~ cells from each of the P815-5-azacytidineinduced tum-clones (J or D) or TA3-5-azacytidine-induced turn-clones (K or P), respectively. 14 d later, the spleens were removed, pooled, and restimulated in vitro with mitomycin C-treated cells identical to the initial priming clone. 5 d later, the cells were harvested and used as effectors against different targets, in an nlIndium release assay (18) . 
Assessment of Mutagenic

Assessment of DNA 5-Methylcytosine Content by High Performance Liquid Chromatography (HPLC).
The HPLC method used to quantitate 5-methylcytosine was based on that described by Flateau et al. (21) . Cells were labeled with [6-'H]-uridine by incubating 2 × 105 cells/ml with 2 #Ci/ml uridine. A Beckman HPLC system with a Altex ULTRASIL-CX column was used with isocratic elution using 0.035 M KH2PO4, pH 2.5 containing 5% vol/vol MeOH at a flow rate of 2.5/min. The elution of the bases was measured using known standards. The fractions containing the cytosine (C) and 5-methylcytosine (MC) were assayed for radioactivity by scintillation counting. Percentage MC (21) was calculated as follows: % MC = cpm (MC)/cpm (C) + cpm (MC) × 100%.
Results
Frequency of Selection of Turn-Clones.
Three different tumors treated with 5-azacytidine were cloned and assessed for the turn-phenotype, and the results compared to those obtained using conventional mutagens (MNNG or EMS) with the same tumors. The frequency of selection of rum-variants derived after 5-azacytidine treatment (and compared to frequencies seen after mutagen treatment) is shown in Table I . 15 randomly selected tum-variants of TA3 were reinjected into A/J mice or BALB/c nude mice on two subsequent occasions. 14 of these clones retained their tum-phenotype. Of these 14 clones, 4 were injected an additional four times over a six-month period and remained stable for their turn-phenotypes. Of these four, however, only one has remained turnafter nine months in culture. No turn-MDAY-D2 clones were detected after 5-azacytidine treatment. This is identical to what was observed when the same tumor was treated once with EMS or MNNG as shown in Table I , and as described previously. Tum-variants from MDAY-D2 could be generated, but only at low frequency after a double (sequential) treatment with the mutagen (7). Double (sequential) treatment with 5-azacytidine did not generate any MDAY-D2 turn-variants. All four tum-P815 clones that were isolated after 5-azacytidine treatment retained their turn-phenotype after three months in culture.
Immunogenicity of Turn-Clones Derived after 5-Azacytidine Treatment.
In order to demonstrate that the failure of turn-clones to grow was due to an immunological change, eight of the TA3 and four of the P815 5-azacytidine-induced tumclones were injected into T ceil-deficient athymic (nude) mice. All of these clones, which failed to grow in syngeneic normal animals, grew progressively and killed the nude mouse host. Furthermore, all TA3 5-azacytidine-induced turnclones (N = 23) and P815 5-azacytidine-induced turn-clones (N = 4) were able to protect syngeneic hosts against challenge with the parent tumor. Thus A/J strain mice preimmunized with individual TA3 5-azacytidine-induced turnclones and subsequently challenged with ordinarily lethal doses of TA3 tumor cells have survived indefinitely (>10 months) without evidence of tumor recurrence. Furthermore, this protection was specific in that animals immunized with a 5-azacytidine-induced turn-clones of TA3, were not protected against a subsequent challenge with an unrelated A strain tumor, i.e., the H6TBJ-750 hepatoma (data not shown).
All the 5-azacytidine-induced turn-variants tested (for TA3 N --6; for P815 N = 4) were able to induce CTL response after appropriate secondary stimulation (Table II) . While this response was sometimes less than that seen with EMS-or MNNG-derived turn-clones (7), it was far greater than that seen in animals injected with the parent tumor (Table II) . In addition, as noted above, this CTL response was sufficient for the specific protection against parent tumor challenge in vivo.
Evidence That 5-Azacytidine Is Not Mutagenic in Murine Tumor Cells. It is evident, from these experiments, that 5-azacytidine, which has been shown to be nonmutagenic, or very poorly so, in non-neoplastic mouse C3H 10TI/2 cells or Chinese hamster lung (V79) cells (22) is as effective in selecting immunogenic turn-variants as EMS or MNNG (or as ineffective, in the case of MDAY-D2). Because the mutagenic effects of 5-azacytidine on mouse tumor lines have not yet been assessed, we tested its effect on the frequency of drug-resistant mutants Table III , EMS, as expected, produced a significant increase in Oua R, 6-TG r or 2-D-gait colonies. However, 5-azacytidine had no effect, or only a negligible one, in all cases. Thus, the results confirm those of Landolph and Jones (22) , and strongly imply that 5-azacytidine is a poor inducer of various types of point mutations in mouse tumor cell lines. Table IV , we have made some preliminary analyses, using HPLC, of the levels of 5-methylcytosine in EMS or 5-azacytidinetreated tumor cells. The results show that a decrease in methylcytosine content was observed in 5-azacytidine-treated cells (of ~15%), as expected, though it was not as great as we had anticipated based on the results of others (where decreases of about 50% are often observed, e.g., references [23] [24] [25] . When EMStreated cells were examined, no decrease was detected in MDAY-D2 cells (from which turn-variants are not derived after one-step EMS treatment). A small decline was noted in the EMS-treated TA3 cells; however, this was not assessed to be statistically significant.
Effects of 5-azacvtidine or EMS on the Levels of 5-Methylcytosine in DNA of TA3 or MDAY-D2 Cells. As shown in
Discussion
The purpose of these studies was to determine whether the treatment of murine tumor cells with 5-azacytidine, like EMS, would result in the derivation of clones at high frequency unable to form tumors in normal syngeneic hosts. Such selections had previously been reported by Boon and his colleagues (1-6) after treatment of routine tumors with the alkylating agent MNNG, and by ourselves, using EMS (7). While the availability of such so-called tum-variants is of considerable interest in itself, the expression of unique tumor antigens by each turn-clone (1-6)in conjunction with their derivation at such high frequencies raises several important immunologic and genetic questions (11) . One of the most obvious of these relates to the genetic mechanism of the phenomenon. Neither the presence of numerous unique tumor antigens nor the extraordinarily high frequency of selections can be explained on the basis of classic point mutations.
We therefore turned to a different means of deriving such variants using an agent--5-azacytidine--that is only weakly, if at all, mutagenic in eucaryotic cells but which can nevertheless drastically alter gene expression by causing DNA hypomethylation. The results presented herein describe our findings and suggest that the induction of turn-variants by treatment with conventional mutagens and 5-azacytidine most likely occurs by a common mechanism. Thus, we have demonstrated that: (a) treatment of tumor cell lines with 5-azacytidine can lead to the selection at high frequency of turn-variants; (b) those lines (e.g., TA3) in which >80% of the clones express the turn-phenotype after EMS treatment also gave rise to >80% turn-clones after 5-azacytidine treatment. Furthermore, if EMS was ineffective in deriving tum-clones from a particular tumor (e.g., MDAY-D2), the same was true after 5-azacytidine treatment; (c) 5-azacytidineinduced turn-variants grew readily in nude mice and induced strong CTL responses in culture--like the mutagen-induced tum-variants (7). We have also obtained recent evidence which suggests that the new 5-azacytidine-induced tumor antigens on the turn-clones are--as with EMS-highly polymorphic (Frost, unpublished observations) . Despite these similarities, we found 5-azacytidine not to be significantly mutagenic when tested on our mouse tumor cell lines (Table  III) . This is in stark contrast to the results obtained with EMS.
In comparing the results using 5-azacytidine or the mutagens EMS or MNNG, it is important to note that Wilson and Jones (15) have demonstrated that these same mutagens can themselves cause hypomethylation of DNA. Similarly, Boehm and Drahovsky (16) have shown that MNNG can inhibit DNA methylation in viable human leukemia cells. These latter authors have also found hypomethylation of DNA in clones of P815 mastocytoma cells derived after treatment in vitro with the alkylating agent/carcinogen N-acetoxy-N-2-acetylamino fluorene, i.e., AAAF (17) . Since 5-azacytidine is a very strong hypomethylating agent but such a poor mutagen in eucaryotic cells (22) , the most plausible mechanism for the observed in Vivo effects reported here is the influence both types of agents (i.e., 5-azacytidine or the alkylating agent mutagens) may have on DNA methylation levels and patterns, although this remains to be definitively established. In this regard our initial analyses of the 5-methylcytosine content of DNA are too preliminary to make any conclusions.
Assessment of overall levels of 5-methylcytosine in DNA may however be uniformative (23) especially.since even small decreases may be sufficient to cause transcriptional activation of genes necessary for the expression of turn-phenotype. Other assays, and the examination of many independent clones (17) using restriction endonucleases and cDNA gene probes may be necessary to establish any clear relationship between DNA hypomethylation and the generation of turn-variants by mutagens. Thus, until gene probes for the appropriate tumor antigens exist, it will be impractical to evaluate this possibility. It should also be noted that even in a situation where carcinogen or mutagen treatment of tumor cells leads to an overall higher level of 5-methylcytosine content in the cells, many of the cells (i.e., clones) in the population may actually be hypornethylated (17) . Thus, even the small (4%) decrease in methylcytosine content of EMS treated cells may be "significant" in the sense that it may be a reflection of far greater decreases in the many individual clones of the EMS-treated cells. It is also worth emphasizing that some authors have reported rapid hypomethylation followed by an equally rapid de novo methylation in some 5-azacytidine-induced tumor lines, e.g., Friend virus leukemia cells (24) . In contrast, others report recovery of methylation levels is far more protracted, e.g., 10-12 wk in AKR lymphoma cells (25) . Just where our lines stand in this connection remains to be determined.
It is therefore clear that there are many complexities to be considered when evaluating the methylation status of the treated tumor cell populations. Nevertheless, we feel that the most plausible hypothesis, at this time, to account for our findings is the induction of DNA hypomethylation and subsequent transcriptional activation of dormant genes coding for tumor antigens. This hypothesis also has the attractive feature of providing an explanation for why many turnclones revert to the turn + phenotype, as described here and reported previously by us (7, 26) . Such reversions, which are sometimes rapid (26) , were difficult to explain on the basis of a mutational (i.e,, base sequence change in DNA) origin for turn-clones. However, they are much more understandable in the context of what is known about the heritability of altered methylation patterns and levels, namely that they are somatically inherited with a high but not perfect fidelity (14, 25) so that they can rapidly, or more gradually, return to normal, or near normal, levels. Hence the term "stable" should be applied loosely to heritable phenotypic changes brought about by hypomethylation. Methylation levels may return to normal values over a period of days, weeks, or months, with a resultant reversion of certain induced phenotypic traits, as shown recently by Gasson et al. (25) . These authors found glucocorticoid-sensitive clones derived from a 5-azacytidine-treated steroid-resistant mouse lymphoma line. Such glucocorticoidsensitive clones were generated at very high frequency (10%), but gradually reverted to a resistant phenotype over a period of 2-3 months in culture (25) . We have noted similar sorts of phenotypic reversions in our turn-variants, whether induced by 5-azacytidine or EMS (26) .
We would also like to stress the implications these findings may have in regard to possible "epigenetic" origins of tumor progression (26) (27) (28) (29) . Gradual hypomethylation of DNA, possibly caused by carcinogen accumulation, chemotherapeutic drugs, or local environmental conditions, could result in progressive and random activation of many genes, thus potentially resulting in neoplastic cell populations of increasing diversity (26, 27, 29) . From this population, the emergence of new (and possibly more malignant) subpopulations having heritable changes (of varying stability) in a particular phenotype, or set of phenotypes, could emerge by selection pressures or simple competitive advantages. In some cases, the change may render the cells less malignant because of, for example, an immunological alteration (as shown here), whereas in other cases, the genes activated may make the cells more malignant. Indeed, we have noted that among our 5-azacytidine-treated clones which remain tumorigenic, some are actually more malignant than the parent tumor, as defined by metastatic aggressiveness (26) . L. Olsson ~ has reported similar findings. Thus, it would appear that 5-azacytidine treatment of tumor cell populations can cause either a short-term or long-term heritable decrease in relative aggressiveness (as defined by progressive growth at the site of inoculation), or an increase, based on their ability to metastasize. These opposing changes can be detected by the testing of many Olsson, L., andJ. Forchhammer. Induction of the metastatic phenotype in a mouse tumor model by 5-azacytidine and characterization of an antigen associated with metastatic activity. Submitted for publication.
individual clones derived from 5-azacytidine-treated parent tumor cell populations.
Summary
Highly immunogenic "tum-" (non-tumorigenic in normal syngeneic hosts) clonal variants can be selected from a variety of poorly immunogenic and highly tumorigenic mouse cell lines at very high frequencies (e.g., >80%) after treatment in vitro with chemical mutagens such as ethyl methanesulfonate (EMS) or Nmethyl-N'-nitro-N-nitrosoguanidine (MNNG). We herein demonstrate that the same result can be obtained with the poorly mutagenic cytidine analogue, 5-azacytidine, a strong DNA hypomethylating agent. 5-Azacytidine and EMS were equally and comparably effective, or ineffective, in inducing turn-variants from three different highly tumorigenic mouse cell lines. Like mutagen-induced tumvariants, those obtained after 5-azacytidine treatment generated usually strong cytolytic T lymphocyte (CTL) responses in vitro, and could grow in immunosuppressed (nude mouse) hosts. However, pretreatment of the tumor cell lines with 5-azacytidine did not cause significant increases in mutations at several independent drug-resistant gene loci, whereas EMS did. It is known that treatment of cells with 5-azacytidine can induce transcriptional activation of "silent" genes through a reduction of DNA 5-methylcytosine content, a process that can also be effected by mutagenic DNA alkylating agents such as EMS and MNNG. We therefore hypothesize that an "epigenetic" mechanism (DNA hypomethylation) leading to activation and expression of genes coding for potential tumor antigens is involved in the generation at high frequency of tum-variants after "mutagen" treatment. The implications of these findings to mechanisms of tumor progression and the generation of tumor heterogeneity are discussed.
